NEUROCRINE BIOSCIENCES INC - 23 Feb 2023 Form 4 Insider Report for Voyager Therapeutics, Inc. (VYGR)

Reporting relationship: 10%+ Owner
Issuer ticker: VYGR
Reported as of: 23 Feb 2023
Net transaction value: +$39,032,821
SEC form: 4
Accepted by SEC: 24 Feb 2023, 05:15:24 UTC
Source filing: View source filing
Reporting owner signature: /s/ Darin Lippoldt, Chief Legal Officer & Corporate Secretary

Filing notes and source

Key filing fact

NEUROCRINE BIOSCIENCES INC filed Form 4 for Voyager Therapeutics, Inc. (VYGR) on 24 Feb 2023.

Key facts

This page summarizes NEUROCRINE BIOSCIENCES INC's Form 4 filing for Voyager Therapeutics, Inc. (VYGR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 Feb 2023, 05:15.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$39,032,821.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VYGR transaction

Common Stock

Purchase

Transaction value: $39,032,821
Shares: +4,395,588
Change %: +105%
Price: $8.88
Shares after: 8,575,316
Date: 23 Feb 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The purchase price was determined in accordance with that certain Stock Purchase Agreement dated January 8, 2023, between the reporting person and the issuer.